Qiagen sweetens Cellestis bid by 7% to speed up completion
This article was originally published in Clinica
Executive Summary
Qiagen has increased its proposed price for the purchase of Australian "pre-molecular" testing specialist Cellestis by 7%, in order to close the matter "as quickly as possible". It is now offering Aus$3.80 ($4.02) per share, or around Aus$365m in total, compared with its previous bid of Aus$3.55 per share, or Aus$341m in total, which it agreed with the Cellestis board in April under a scheme implementation deed (www.clinica.co.uk, 4 April 2011).
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.